Predictors of readmission and impact of same-day discharge in holmium laser enucleation of the prostate.

Abstract

Holmium enucleation of the prostate (HoLEP) is becoming the gold standard for the treatment of benign prostatic hyperplasia (BPH). Our objective was to identify predictors of 30-day readmission and the impact of same-day discharge after HoLEP. Using NSQIP data from 2011 to 2019, we identified men who underwent HoLEP for the treatment of BPH. We compared patients based on time of discharge and readmission status. We used multivariable logistic regression analysis (MLRA) to identify independent factors associated with 30-day readmission. A total of 3,489 patients met inclusion criteria with 833 (23.88%) being discharged within 24hours and 2,656 (76.12%) discharged after 24hours. There were 158 (4.53%) 30-day readmissions, mostly due to hematuria and urinary tract infection. Patients being readmitted were older (72 vs. 70years old, P=0.001), were more likely to have preoperative anemia (36.7% vs. 23.1%; P<0.001), chronic kidney disease (29.7% vs. 19.7%; P<0.001), bleeding disorder (10.8% vs. 2.8%; P<0.001), higher American Society of Anesthesiologists (ASA) scores (≥3: 70.3% vs. 46.7%; P<0.001) and a higher frailty burden (5-item modified frailty index [5i-mFI]≥2: 36.1% vs. 19.1%; P<0.001) compared to their counterparts. Factors independently associated with 30-day readmission were bleeding disorder (OR 2.89; 95% CI 1.63-5.11; P<0.001), 5i-mFI ≥ 2 (OR 1.67; 95% CI 1.03-2.71; P=0.038) and an ASA score ≥3 (OR 1.80; 95% CI 1.21-2.70; P=0.004); however, same-day discharge was not found to be a significant predictor of 30-day readmissions. The overall readmission rate after HoLEP is low. Patients discharged within 24hours have similar rates of readmission compared to patients discharged after 24hours. We found bleeding disorder, frailty burden, and ASA score to be independent predictors of 30-day readmission.